Login to Your Account

Financings NEWS
TOKYO – Two Japanese pharma companies are investing tens of millions into a new biotech venture fund created by Remiges Biopharma Fund LP as they look for new collaborations outside Japan.
Contrafect Corp. priced its initial public offering (IPO) Tuesday for gross proceeds of $36 million to advance its early stage pipeline against drug-resistant pathogens, including a lead lysine candidate for Staphylococcus aureus bacteremia and an antibody combo candidate for influenza.
In a two-step scheme, specialty vaccine developer Paxvax Inc. acquired the FDA-approved oral typhoid vaccine Vivotif from Crucell Switzerland AG and financed the deal with $50 million in secured debt from an investment fund managed by Pharmakon Advisors and $12 million in an extension of its series B preferred stock.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: